Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma

Completed · Phase 2

Conditions studied: Pancreatic Cancer

In brief

This is an open-label, phase 2 non-comparative study to assess the safety, tolerability, and preliminary efficacy of nal-IRI in combination with other anticancer therapies in patients not previously treated for metastatic pancreatic adenocarcinoma. This study will assess the following regimen: • nal-IRI + 5-fluorouracil (5-FU)/leucovorin (LV) + oxaliplatin The study will be conducted in two parts: Part 1, consisting of an initial dose exploration (Part 1A) followed by dose expansion (Part 1B) of the irinotecan liposome injection +5-FU/LV + oxaliplatin regimen and Part 2, consisting of a comparison of irinotecan liposome injection-containing regimen versus nab-paclitaxel plus gemcitabine. The comparative Part 2 was removed in a protocol amendment, dated 11 April 2018 (Version 6.0), before it was initiated, as this comparative part of the study is being undertaken as a stand-alone phase III study D-US-60010-001. This CSR only pertains to the single-arm dose exploration and dose expansion Part 1 results and no further reference is made to the comparative Part 2.

Key facts

Study ID

NCT02551991

Run by

Ipsen

People needed

56

Starts

2015-10-19

Expected to finish

2021-02-15

Last updated by the study team

2022-10-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically or cytologically confirmed adenocarcinoma of the pancreas that has not been previously treated in the metastatic setting
• Unresectable, locally advanced or metastatic disease; diagnosed within 6 weeks prior to screening
• At least one tumor lesion measurable by CT or MRI scan (according to RECIST v1.1)
• ECOG performance status of 0 or 1 at screening and within 72 hours prior to first dose if first dose occurs more than 72 hours post-screening
• Adequate hematological, hepatic, renal and cardiac function
• Recovered from the effects of any prior surgery or radiotherapy
• Patient has a Karnofsky performance status (KPS) ≥ 70 at Screening, and within 72 hours prior to date of first dose if first dose occurs more than 72 hours after screening (Part 1B only)

You may not qualify if…

• Prior treatment of pancreatic cancer in the metastatic setting (or locally advanced setting) with surgery (placement of stent is allowed), radiotherapy, chemotherapy or investigational therapy
• Prior treatment of pancreatic cancer with chemotherapy in adjuvant setting, except those where at least 12 months have elapsed since completion of the last dose and no persistent treatment-related toxicities present
• Uncontrolled Central Nervous System (CNS) metastases
• Clinically significant gastrointestinal disorder
• History of any second malignancy in the last 3 years. Patients with prior history of in-situ cancer or basal or squamous cell skin cancer are eligible
• Presence of any contraindications for nal-IRI, irinotecan, 5-FU, leucovorin, oxaliplatin
• Use of strong CYP3A4 or inducers or presence of any other contra indications for irinotecan
• Pregnant or breast feeding
• Neuroendocrine or acinar pancreatic carcinoma
• Serum albumin < 3 g/dL at screening visit and within 72 hours prior to first dose if first dose occurs more than 72 hours post screening
• Patients with symptoms and signs of clinically unacceptable deterioration of primary disease at time of screening
• Previous treatment with irinotecan-based, nab-paclitaxel-based or gemcitabine-based resulting in disease progression

Where it is running

• University of South Alabama — Mobile, Alabama, United States
• University of South Alabama - Mobile — Mobile, Alabama, United States
• Arizona Center for Cancer Care — Avondale, Arizona, United States
• Mayo Clinic Hospital — Phoenix, Arizona, United States
• UCLA Hematology Oncology - Ventura — Los Angeles, California, United States
• University of California Irvine Medical Center (UCIMC) - Chao Family Comprehensive Cancer Center — Orange, California, United States
• University of Colorado (CU) Cancer Center - Anschutz Cancer Pavilion — Aurora, Colorado, United States
• Mayo Clinic Cancer Center — Jacksonville, Florida, United States
• University of Miami — Miami, Florida, United States
• Eastern Maine Medical Cancer Care — Brewer, Maine, United States
• Maryland Oncology Hematology — Silver Spring, Maryland, United States
• Lahey Hospital & Medical Center — Burlington, Massachusetts, United States
• Mayo Clinic Cancer Center - Rochester — Rochester, Minnesota, United States
• Oncology Hematology West PC dba Nebraska — Omaha, Nebraska, United States
• US Oncology - Comprehensive Cancer Centers of Nevada (CCCN) — Las Vegas, Nevada, United States
• Holy Name Medical Center — Teaneck, New Jersey, United States
• Roswell Park Cancer Institute — Buffalo, New York, United States
• Oncology/Hematology Care Clinical Trials, LLC — Cincinnati, Ohio, United States
• University of Oklahoma Health Sciences Center (OUHSC) Stephenson Cancer Center — Oklahoma City, Oklahoma, United States
• Willamette Valley Cancer Institute & Research Center — Eugene, Oregon, United States
• Gettysburg Cancer Center — Gettysburg, Pennsylvania, United States
• Greenville Health System — Greenville, South Carolina, United States
• Medical Group of the Carolinas - Spartanburg Regional Health Services — Spartanburg, South Carolina, United States
• Texas Oncology Methodist Dallas Cancer Center — Dallas, Texas, United States
• Texas Oncology-Fort Worth 12 Ave — Fort Worth, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.